🧬 Semaglutide May Slow Biological Aging, First Randomized Human Evidence Suggests

GLP-1 drugs such as semaglutide are already well known for treating obesity and type 2 diabetes. Now, researchers at UC San Diego report the first randomized placebo-controlled evidence that the drug may also slow biological aging — at least as measured by epigenetic aging clocks.

The team analyzed DNA methylation data from a 32-week, double-blind clinical trial involving 108 adults with HIV-associated lipohypertrophy. Participants received either weekly semaglutide injections or placebo. Researchers then used multiple epigenetic clocks — molecular biomarkers that estimate biological aging from chemical modifications to DNA — to evaluate changes in aging rate.

The results, published in Nature Communications, showed that semaglutide significantly slowed several independent measures of biological aging. On the DunedinPACE clock, the pace of aging slowed by about 9%. Significant improvements were also observed with the PCGrimAge clock, which is associated with mortality and age-related disease risk.

A separate 24-week pilot study in people with HIV and fatty liver disease reported that about 42% of participants showed a reduction in DunedinPACE after semaglutide treatment, although that study had no placebo control and should be interpreted cautiously.

In simple terms: epigenetic clocks don’t measure your chronological age. They estimate how quickly the molecular processes associated with aging are progressing. A 9% reduction means these biomarkers changed more slowly during treatment — not that people became 9% younger.

Scientists think several mechanisms may contribute. Semaglutide reduces chronic inflammation, decreases harmful visceral fat, and improves metabolic health — all processes linked to accelerated aging. These changes may influence molecular pathways involved in aging across multiple organ systems.

Key findings:

• ~9% slower pace of aging on the DunedinPACE clock
• Significant improvement in the PCGrimAge mortality-risk clock
• Similar effects across several independent epigenetic aging clocks
• A separate pilot study found ~42% of participants showed slower epigenetic aging after treatment

The study also has important limitations. This was a post hoc exploratory analysis, not a trial originally designed to study aging. Participants all had HIV-associated lipohypertrophy, a condition associated with accelerated biological aging, so the findings cannot yet be generalized to healthy individuals. Most importantly, improvements in epigenetic clocks do not prove that semaglutide extends lifespan or healthspan. Those questions will require much longer clinical studies.

Why it matters: Tens of millions of people already take GLP-1 drugs worldwide. If future studies confirm these findings in broader populations, semaglutide could become one of the first widely used medications shown to influence molecular biomarkers of human aging — extending its impact far beyond weight loss.

📄 https://www.nature.com/articles/s41467-026-72861-3

#Longevity #Semaglutide #GLP1 #Aging #Healthspan